

Financial results for the the year ended March 31, 2024

May 9, 2024

1. Financial results for the year ended March 31, 2024

2. Forecast for the year ending March 31, 2025

The year ended March 31, 2024: Summary

Revenue ¥717.2B

• YoY: Up ¥89.1B (Up ¥12.2B vs. previous forecast)

- Revenue grew in all segments but the Components Business.
- In the Imaging Products Business, revenue grew on increased sales volumes of mirrorless cameras and interchangeable lenses.
- In the Precision Equipment Business, revenue grew on increased sales volumes of ArF immersion lithography systems.
- In the Digital Manufacturing Business, revenue grew on contribution from expanded sales at SLM.

Operating profit ¥39.7B

• YoY: Down ¥15.2B (Up ¥3.7B vs. previous forecast)

- In the Imaging Products Business, profit grew on maintained strength.
- Total operating profit declined due to decreased profit in the Components Business and the Precision Equipment Business (lower sales volumes of FPD lithography systems and lower service revenue), and one-time costs in the Healthcare Business and the Digital Manufacturing Business.

Profit attributable to owners of parent ¥32.5B

• YoY: Down ¥12.4B (Up ¥5.5B vs. previous forecast)

Dividends ¥50

- YoY: Up ¥5 (Same as previous forecast)
 - Interim ¥25 and year-end ¥25

Note: Amounts in this statement are rounded down to the hundred millions of yen.

The year ended March 31, 2024: Financial Highlights

	FY2023/3	Previous	FY2024/3	Change		Change	
		Forecast		Amount	%	Amount	%
Billions of Yen	Actual (A)	(Feb. 8) (B)	Actual (C)	(C)-(A)	(C)/(A)	(C)-(B)	(C)/(B)
Revenue	628.1	705.0	717.2	+89.1	+14.2%	+12.2	+1.7%
Operating profit % vs Revenue	54.9 8.7%	36.0 5.1%	39.7 5.5%	-15.2 -3.2P	-27.6%	+3.7 +0.4P	+10.5%
Profit before tax % vs Revenue	57.0 9.1%	37.0 5.2%	42.6 5.9%	-14.4 -3.2P	-25.2%	+5.6 +0.7P	+15.3%
Profit attributable to owners of parent	44.9	27.0	32.5	-12.4	-27.5%	+5.5	+20.6%
% vs Revenue	7.2%	3.8%	4.5%	-2.7P		+0.7P	
FCF	-112.1	-	-10.6	+101.5	-	-	-
ROE	7.4%	4.2%	5.0%	-2.4P	-	+0.8P	-
EPS	¥125.46	¥77.96	¥94.03	-¥31.43	-	+¥16.07	-
Annual Dividends	¥45	¥50	¥50	+¥5	-	±¥0	-
Exchange Rate:	¥135	¥143	¥145		-	n Revenue	
US\$	+133	+143	+175	+3			6.8
EURO	¥141	¥154	¥157		Impact on Op 5.9	erating profit +	1.3

FCF was negative as construction costs for our new HQ building outweighed a substantial improvement in operating CF and the sale of ¥16.6B in cross-shareholdings.


Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.3M shares

The year ended March 31, 2024: Performance by Segment

		FY2023/3	Previous	FY2024/3	Change		Change	
			Forecast		Amount	%	Amount	%
Billions of Yen		Actual (A)	(Feb. 8) (B)	Actual (C)	(C)-(A)	(C)/(A)	(C)-(B)	(C)/(B)
Imaging Products	Revenue	227.1	275.0	279.7	+52.6	+23.2%	+4.7	+1.7%
Business	Operating profit	42.2	44.0	46.5	+4.3	+10.3%	+2.5	+5.8%
Business	% vs Revenue	18.6%	16.0%	16.6%	-2.0P		+0.6P	
Procision Equipment	Revenue	203.2	213.0	219.3	+16.1	+7.9%	+6.3	+3.0%
Precision Equipment Business	Operating profit	24.5	12.0	15.1	-9.4	-38.2%	+3.1	+26.5%
Busilless	% vs Revenue	12.1%	5.6%	6.9%	-5.2P		+1.3P	
	Revenue	99.3	105.0	107.8	+8.5	+8.5%	+2.8	+2.8%
Healthcare Business	Operating profit	11.5	6.5	5.3	-6.2	-53.5%	-1.2	-17.1%
	% vs Revenue	11.7%	6.2%	5.0%	-6.7P		-1.2P	
	Revenue	53.0	47.0	47.0	-6.0	-11.4%	±0.0	+0.0%
Components Business	Operating profit	22.0	15.0	16.8	-5.2	-23.8%	+1.8	+12.2%
	% vs Revenue	41.6%	31.9%	35.8%	-5.8P		+3.9P	
Digital Manufacturing	Revenue	42.0	62.0	59.9	+17.9	+42.4%	-2.1	-3.3%
Digital Manufacturing	Operating profit	-10.1	-13.0	-15.8	-5.7	-	-2.8	-
Business	% vs Revenue	-24.1%	-21.0%	-26.4%	-2.3P		-5.4P	
Others	Revenue	3.2	3.0	3.2	±0.0	+2.2%	+0.2	+9.9%
(incl. Corporate expenses, etc.)	Operating profit	-35.3	-28.5	-28.3	+7.0	-	+0.2	-
	Revenue	628.1	705.0	717.2	+89.1	+14.2%	+12.2	+1.7%
Consolidated	Operating profit	54.9	36.0	39.7	-15.2	-27.6%	+3.7	+10.5%
	% vs Revenue	8.7%	5.1%	5.5%	-3.2P		+0.4P	

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Imaging Products Business




• Revenue: Up ¥52.6B YoY (Up ¥4.7B vs. previous forecast)

- DCIL market expanding mainly in China.
- Nikon's new products (Z 8 and Z f) are selling well.
- Nikon advanced its shift to mirrorless cameras and interchangeable lenses.
- Revenue substantially grew YoY as sales volumes of mirrorless cameras and interchangeable lenses grew and ASP rose. The weaker yen also helped.
- Revenue beat the previous forecast due to changes in product mix and the weaker yen.

• Operating Profit: Up ¥4.3B YoY (Up ¥2.5B vs. previous forecast)

- Operating profit grew YoY as the effects of revenue growth outweighed increased parts procurement prices and sales promotion costs.
- Operating profit beat the previous forecast because of increased revenue.

The year ended March 31, 2024: Precision Equipment Business



• Revenue: Up ¥16.1B YoY (Up ¥6.3B vs. previous forecast)


- Revenue grew YoY in the overall Precision Equipment Business as higher sales volumes in mainly ArF immersion lithography systems outweighed a substantial decline in FPD lithography system sales volumes due to customers reining in capital expenditure.
- Compared to previous forecast, sales volumes of refurbished lithography systems and service revenue increased.

• Operating Profit: Down ¥9.4B YoY (Up ¥3.1B vs. previous forecast)

- Operating profit for the overall Precision Equipment Business declined YoY on lower sales volumes of FPD lithography systems and lower service revenue in the Semiconductor Lithography Business.
- Operating profit beat the previous forecast because of increased revenue.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Healthcare Business



* See Contingent Liabilities (page 30) of our Consolidated Financial Results.


• Revenue: Up ¥8.5B YoY (Up ¥2.8B vs. previous forecast)

- Revenue grew on increased sales in Life Science and Contract Cell Manufacturing as well as the weaker yen.
- In Life Science, we made progress developing the private sector market and delivering solutions for drug discovery support. However, sales decelerated in 2H on increased market uncertainty.
- In Eye Care, sales was flat YoY as expanded sales in China and the rest of Asia was offset by the disappearance of major deals struck.
- In Contract Cell Manufacturing, multiple projects progressed smoothly, and sales expanded.

Operating Profit: Down ¥6.2B YoY (Down ¥1.2B vs. previous forecast)

- Operating profit declined YoY as rising procurement costs, higher R&D expenditures and investments in people and IT systems, and the accrual of ¥4.1B in one-time costs outweighed profit boosting effects of increased revenue.
- The one-time costs were primarily in Eye Care. A ¥1.4B provision* booked in Q2, related survey expenses, and the disposal and write-down of inventories.
- Results missed previous forecast due to increased one-time costs in Eye Care and smaller sales volumes of microscopes.

The year ended March 31, 2024: Components Business



• Revenue: Down ¥6.0B YoY (Same level as previous forecast)


- Sales declined YoY in EUV related components and optical parts due to postponed capital expenditures and reduced utilization rates by semiconductor device makers.
- Encoder sales declined YoY due to stagnant demand in the factory automation market.
- Sales of photomask substrates for FPD declined YoY due to market stagnation.

Operating Profit: Down ¥5.2B YoY (Up ¥1.8B vs. previous forecast)

- Operating profit beat the previous forecast due to product mix improvement.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Digital Manufacturing Business



• Revenue: Up ¥17.9B YoY (Down ¥2.1B vs. previous forecast)

- Revenue grew due to the full-year contribution from SLM.
- On a standalone basis, SLM revenue grew 15%* YoY, a record high.
- Results missed previous forecast due to the impact on the Industrial Equipment Business from market stagnation in semiconductors and electronic components.

Operating Profit: Down ¥5.7B YoY (Down ¥2.8B vs. previous forecast)

- Operating losses expanded YoY. In the Advanced Manufacturing (ADM) Business, ¥4.0B in intangible-asset amortization costs resulting from the SLM acquisition and increased costs launching a base of operations in the US outweighed reductions in acquisition and restructuring costs.
- On a standalone basis, SLM turned profitable for the first time in Q4.
- Compared to previous forecast, the ADM Business progressed as planned. In the Industrial Metrology Business, we forecasted being profitable, but results were negative. That was due to missing plan for revenue and the accrual of ¥1.7B in one-time costs including impairment of development assets and disposal and write-down of inventories due to rationalization of unprofitable products.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

^{*} SLM standalone revenue growth (%) is expressed based on local currency (EURO).

1. Financial results for the year ended March 31, 2024

2. Forecast for the year ending March 31, 2025

Forecast for the year ending March 31, 2025: Summary

Revenue ¥745.0B

• YoY: Up ¥27.8B

- The Imaging Products Business revenue to grow on increased sales volumes and the consolidation of RED Digital Cinema (RED).
- The Healthcare Business and the Digital Manufacturing Business to further expand businesses.
- The Precision Equipment Business and the Components Business revenue to decline because of postponed investments at some semiconductor customers.

Operating profit ¥35.0B YoY: Down ¥4.7B

- We expect operating profit to decline as profit growth and a reduction in one-time costs in the Healthcare Business and the Digital Manufacturing Business are outweighed by profit contraction in the Imaging Products Business and an increase in corporate expenses (¥5.0B HQ relocation costs and IT-related investments).

Profit attributable to owners of parent ¥30.0B

YoY: Down ¥2.5B

Dividends ¥55

- Annual dividend planned: ¥55, up ¥5 YoY (interim ¥25 and year-end ¥30)
 - Step up dividends to reach our target of annualized ¥60 in the last fiscal year of the Medium-Term Management Plan.

Exchange rate

• US\$ ¥145, EURO ¥155

Forecast for the year ending March 31, 2025: Financial Highlights

	FY2024/3	FY2025/3	Change		
Billions of Yen	Actual (A)	Forecast (B)	Amount (B)-(A)	% (B)/(A)	
Revenue	717.2	745.0	+27.8	+3.9%	
Operating profit % vs Revenue	39.7 5.5%	35.0 4.7%	-4.7 -0.8P	-12.0%	
Profit before tax % vs Revenue	42.6 5.9%	40.0 5.4%	-2.6 -0.5P	-6.3%	
Profit attributable to owners of parent	32.5	30.0	-2.5	-7.9%	
% vs Revenue ROE	5.0%	4.0%	-0.5P -0.7P	-	
EPS	¥94.03	¥86.59	-¥7.44	-	
Annual Dividends	¥50	¥55	+¥5	-	
Exchange Rate: US\$	¥145	¥145	Impact on Revenue -0.6		
EURO	¥157	¥155	Impact on Operating profit -0.3		

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.5M shares

Shareholder Returns Policy in the period of the Medium-Term Management Plan

	FY2022/3	FY2023/3	FY2024/3	FY2025/3	FY2026/3
		N	Medium-Term Manag	ement Plan (4 years)
	¥40	¥45 (Up ¥5)	¥50 (Up ¥5)	¥55 planned (Up ¥5)	¥60 target
Dividends	Year-End ¥20 Interim ¥20	Year-end ¥25 Interim ¥20	Year-end ¥25 Interim ¥25	Year-end ¥30 Interim ¥25	Annual ¥60
Share buyback	-	¥30.0B (Approx. 5.7% of outstanding shares)	-	Opportunistic shar ¥30.0B+ during pe Medium-Term Man	eriod of our
Cancellation of treasury stock	-	26M shares (7.6% of outstanding shares before cancellation)	-	Repurchased our s cancelled in	
Total shareholder returns	34.4%	102.0%	53.2%	Targeted 40	% or higher
Sale of cross- shareholdings (Resource of buyback)	¥19.9B	¥1.2B	¥16.6B	Sell more mo	ving forward

Total shareholder returns has been trending at or above the targeted 40%. Step up dividends to reach annualized ¥60 in FY2026/3.

Revision of business segment (From FY2025/3)

Old Segment	Business Unit (BU)			Busin	ess Unit (BU)	New Segm	
Imaging Products	Imaging Pro	Imaging Products BU		Imaging Products BU		Imaging Produc	
	Precision	FPD Lithography BU		Precision Equipment Group	Precision FPD Lithography BU		
Precision Equipment	Equipment Group	Semiconductor Lithography BU			Semiconductor Lithography BU	Precision Equipmen	
Healthcare	Healthcare B	U		Healthcare B	U	Healthcare	
	Customized Products BU			Customized Products BU			
Components	Glass BU	Glass BU		Glass BU		Components	
	Digital Soluti	ions BU	$\overline{} \longrightarrow$	Industrial Solutions BU			
Digital	Industrial Mo	etrology BU				Digital	
Manufacturing	Advanced Ma	anufacturing (ADM) BU		Advanced Ma	nufacturing (ADM) BU	Manufacturing	
Others	Others			Others		Others	
Corporate expenses, etc.	Headquarters division of the parent company			Headquarters company	s division of the parent	Corporate experetc.	


Former Industrial Metrology BU to be disclosed as a part of the Components Business. The Digital Manufacturing Business is comprised solely the Advanced Manufacturing (ADM) BU.

Forecast for the year ending March 31, 2025: Forecast by Segment (New Segment)

			FY2025/3	Chai	nge
Billions of Yen		Actual (A)	Forecast (B)	Amount (B)-(A)	% (B)/(A)
Imaging Products	Revenue	279.7	300.0	+20.3	+7.2%
Business	Operating profit	46.5	44.0	-2.5	-5.5%
	% vs Revenue	16.6%	14.7%	-1.9P	
Precision Equipment	Revenue	219.3	215.0	-4.3	-2.0%
Business	Operating profit	15.1	15.0	-0.1	-1.2%
Business	% vs Revenue	6.9%	7.0%	+0.1P	
	Revenue	107.8	115.0	+7.2	+6.6%
Healthcare Business	Operating profit	5.3	11.0	+5.7	+104.1%
	% vs Revenue	5.0%	9.6%	+4.6P	
	Revenue	85.9	85.0	-0.9	-1.1%
Components Business	Operating profit	15.1	17.0	+1.9	+12.4%
	% vs Revenue	17.6%	20.0%	+2.4P	
Digital Manufacturing	Revenue	21.0	28.0	+7.0	+33.3%
Digital Manufacturing Business	Operating profit	-14.0	-9.5	+4.5	-
Busilless	% vs Revenue	-67.1%	-33.9%	+33.2P	
Others	Revenue	3.2	2.0	-1.2	-39.4%
(incl. Corporate expenses, etc.)	Operating profit	-28.3	-42.5	-14.2	-
	Revenue	717.2	745.0	+27.8	+3.9%
Consolidated	Operating profit	39.7	35.0	-4.7	12.0%
	% vs Revenue	5.5%	4.7%	-0.8P	

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2025: Imaging Products Business




• Revenue: Up ¥20.3B YoY

- The overall DCIL market remains stable. The mid/high-end model market is expected to expand.
- We continue to focus on mid/high-end models and expect sales volume and revenue to grow.
- We acquired US cinema camera manufacturer RED in April 2024. We aim to expand the fast-growing professional digital cinema market.

Operating Profit: Down ¥2.5B YoY

- Operating profit to decline on cost increases including RED acquisition-related expenses and R&D.

Forecast for the year ending March 31, 2025: Precision Equipment Business



Revenue: Down ¥4.3B YoY


 We expect to flat revenue YoY overcoming a reduction in ArF lithography systems sales volumes with a substantial increase in sales volumes of G8 FPD lithography systems for high-resolution panels.

Operating Profit: Down ¥0.1B YoY

- Semiconductor lithography system profit to contract on decreased sales volumes of ArF lithography systems. However, the overall Precision Equipment Business operating profit is projected to remain flat YoY on profit growth from an increase in revenue in FPD lithography systems and an improvement in service revenue in the Semiconductor Lithography Business.

Note: From FY25/3, CY24 market scale of semiconductor lithography system includes lithography system for 200mm or smaller.

Forecast for the year ending March 31, 2025: Healthcare Business



• Revenue: Up ¥7.2B YoY

- In Life Science, we expect to grow sales by developing the private sector market and strengthening drug discovery support service, despite concerns about customers reining in investments in the face of elevated interest rates in Western economies and impacts from the US federal budget.
- In Eye Care, projecting sales growth in core North America as well as Asia and all other geographical markets.
- In Contract Cell Manufacturing, projecting revenue growth driven by expansion of existing projects.


Operating Profit: Up ¥5.7B YoY

- Operating profit to grow on increased revenue and decreased onetime costs, including the Eye Care provision*.

Breakdown of one-time costs	FY24/3 Results	FY25/3 Forecast
Provision and related one-time costs in Eye Care (Addition in the provision in the above amount)	¥3.8B (¥1.4B)	¥1.0B (N/A)
Other	¥0.3B	N/A
Total one-time costs	¥4.1B	¥1.0B

^{*} See Contingent Liabilities (page 30) of our Consolidated Financial Results.

Forecast for the year ending March 31, 2025: Components Business



Revenue: Down ¥0.9B YoY

- Projecting a decline in sales of optical components and EUV related components due to a later-than-expected recovery in demand related to semiconductors.
- Sales of photomask substrate for FPD to increase on market recovery.
- Measuring instruments such as video measuring systems and X-ray and CT systems to be flat YoY.

Operating Profit: Up ¥1.9B YoY


 Projecting operating profit growth due to the disappearance of ¥2.0B in one-time costs including the fixed asset impairment losses booked in the Industrial Solutions Business* in the previous year.

Breakdown of one-time costs	FY24/3 Results	FY25/3 Forecast
Former Digital Solutions Business	¥0.3B	N/A
Former Industrial Metrology Business	¥1.7B	N/A
Total Industrial Solutions Business	¥2.0B	N/A

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

^{*} The former Industrial Metrology BU, which had been included in the Digital Manufacturing Business, is disclosed as a part of the Components Business. Effective April 2024, the former Industrial Metrology BU has been integrated with the former Digital Solutions BU and became the Industrial Solutions BU.

Forecast for the year ending March 31, 2025: Digital Manufacturing Business



Revenue: Up ¥7.0B YoY

- The metal 3D printer market is expected to see growth mainly on large-format systems by demand increase in aerospace and defense industries.
- We project revenue growth on strong orders for SLM's largeformat metal 3D printer (NXG series).
- In FY2024/3, SLM's annual orders booked grew 40% YoY, a record high. As of the end of March 2024, the order backlog had grown to ¥10.0B level.

Operating Profit: Up ¥4.5B YoY

- The size of the operating loss is projected to contract on the effects of revenue growth and the disappearance of one-time costs (¥1.8B).
- SLM aims to turn profitable based on full-year EBITDA.

Reference Data

Business segments and major products (New segment)

Segment	Description		Major	products	
Imaging Products Business	Digital camera-interchangeable lens type Interchangeable lens Cinema camera	Mirrorless Camera [Z 8]	Mirrorless Camera [Z f]	[NIKKOR Z 135mm f/1.8 S Plena]	[V-RAPTOR XL [X]]
Precision Equipment Business	FPD lithography system Semiconductor lithography system Alignment station Measuring & inspection system	Sys	hography stem -88S] ArF Immersio [NSR-S6	n Scanner Alignment Stat [Litho Booste	
Healthcare Business	Biological microscope Retinal diagnostic imaging system Contract Cell Manufacturing business	Confocal Microsc [AX/AX		Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT 「Silverstone」	Contract Cell Manufacturing
Components Business	EUV related component Optical parts, Optical components Encoders, Measuring instrument Photomask substrate for FPD	Optical Parts	Optical Components Multi-turn Absolu [MAR-M5]		Photomask Substrates for FPD
Digital Manufactur- ing Business	Metal 3D printer Optical processing machine 3D scanner Contract material processing	Metal 3D Printer [NXG XII 600E]	Material Processing Machine [Lasermeister LM300A]	3D Scanner [Lasermeister SB100]	Contract Material Processing

The year ended March 31, 2024: Financial Highlights

	FY2021/3	FY2022/3	FY2023/3				FY2024/3	3
Billions of Yen	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	451.2	539.6	288.3	339.8	628.1	331.2	386.0	717.2
Operating profit % vs Revenue	-56.2 -12.5%	49.9 9.3%	24.4 8.5%	30.5 9.0%	54.9 8.7%	13.6 4.1%	26.1 6.8%	39.7 5.5%
Profit before tax	-45.3	57.0	26.0	31.0	57.0	15.2	27.4	42.6
% vs Revenue	-10.0%	10.6%	9.0%	9.1%	9.1%	4.6%	7.1%	5.9%
Profit attributable to owners of parent	-34.4	42.6	18.8	26.1	44.9	9.8	22.7	32.5
% vs Revenue	-7.6%	7.9%	6.5%	7.7%	7.2%	3.0%	5.9%	4.5%
FCF	22.9	30.9		-112.1			-10.6	
ROE	-6.4%	7.5%		7.4%			5.0%	
EPS	-¥93.96	¥116.23		¥125.46			¥94.03	
Annual Dividends	¥20	¥40		¥45			¥50	
Exchange Rate: US\$ EURO	¥106 ¥124	¥112 ¥131	¥134 ¥139	¥137 ¥143	¥135 ¥141	¥141 ¥153	¥148 ¥160	¥145 ¥157

The year ended March 31, 2024: Performance by Segment

		FY2023/3			FY2024/3		
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year
Imaging Products	Revenue	114.5	112.6	227.1	137.6	142.1	279.7
Business	Operating profit	22.2	20.0	42.2	25.2	21.3	46.5
Precision Equipment	Revenue	83.3	119.9	203.2	96.0	123.3	219.3
Business	Operating profit	6.2	18.3	24.5	3.2	11.9	15.1
Hankhanya Businasa	Revenue	46.6	52.7	99.3	51.2	56.6	107.8
Healthcare Business	Operating profit	3.6	7.9	11.5	2.7	2.6	5.3
Commonante Business	Revenue	25.6	27.4	53.0	18.7	28.3	47.0
Components Business	Operating profit	11.3	10.7	22.0	5.9	10.9	16.8
Digital Manufacturing	Revenue	16.2	25.8	42.0	26.1	33.8	59.9
Business	Operating profit	-2.8	-7.3	-10.1	-9.5	-6.3	-15.8
Other area	Revenue	1.7	1.5	3.2	1.4	1.8	3.2
Others	Operating profit	1.0	1.6	2.6	0.1	4.3	4.4
	Operating profit	-17.2	-20.8	-38.0	-14.1	-18.7	-32.8
	Broken out: Expense related to investment in growth	-10.1	-11.6	-21.7	-10.2	-10.7	-20.9
Corporate expenses, etc.	Broken out: Expense for administration department	-5.8	-7.7	-13.5	-6.8	-8.0	-14.8
	Broken out: Elimination of intersegment transactions	-1.2	-1.5	-2.7	2.9	0.0	2.9
Consolidated	Revenue	288.3	339.8	628.1	331.2	386.0	717.2
Consolidated	Operating profit	24.4	30.5	54.9	13.6	26.1	39.7

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Quarterly Performance by Segment

		FY2024/3					
Billions of Yen		Q1	Q2	Q3	Q4	Full Year	
Imaging Products	Revenue	74.4	63.2	84.3	57.8	279.7	
Business	Operating profit	15.3	9.9	17.7	3.6	46.5	
Precision Equipment	Revenue	37.3	58.7	58.5	64.8	219.3	
Business	Operating profit	-3.6	6.8	7.9	4.0	15.1	
Healthcare Business	Revenue	25.2	26.0	25.6	31.0	107.8	
Healthcare business	Operating profit	1.8	0.9	0.2	2.4	5.3	
Components Business	Revenue	8.4	10.3	13.6	14.7	47.0	
Components Business	Operating profit	2.4	3.5	5.7	5.2	16.8	
Digital Manufacturing	Revenue	11.9	14.2	14.8	19.0	59.9	
Business	Operating profit	-4.7	-4.8	-3.3	-3.0	-15.8	
Others	Revenue	0.6	0.8	0.9	0.9	3.2	
Others	Operating profit	-0.0	0.1	1.7	2.6	4.4	
	Operating profit	-7.8	-6.3	-9.2	-9.5	-32.8	
	Broken out: Expense related to investment in growth	-5.1	-5.1	-5.1	-5.6	-20.9	
Corporate expenses, etc.	Broken out: Expense for administration department	-3.4	-3.4	-3.5	-4.5	-14.8	
	Broken out: Elimination of intersegment transactions	0.7	2.2	-0.6	0.6	2.9	
Consolidated	Revenue	158.1	173.1	197.7	188.3	717.2	
Consolidated	Operating profit	3.2	10.4	20.8	5.3	39.7	

The year ended March 31, 2024: Quarterly Performance by Segment (New Segment)

		FY2024/3				
Billions of Yen		Q1	Q2	Q3	Q4	Full Year
Imaging Products	Revenue	74.4	63.2	84.3	57.8	279.7
Business	Operating profit	15.3	9.9	17.7	3.6	46.5
Precision Equipment	Revenue	37.3	58.7	58.5	64.8	219.3
Business	Operating profit	-3.6	6.8	7.9	4.0	15.1
Hooltheave Business	Revenue	25.2	26.0	25.6	31.0	107.8
Healthcare Business	Operating profit	1.8	0.9	0.2	2.4	5.3
Componente Business	Revenue	16.0	20.6	22.7	26.6	85.9
Components Business	Operating profit	1.3	3.8	5.6	4.4	15.1
Digital Manufacturing	Revenue	4.3	3.9	5.7	7.1	21.0
Business	Operating profit	-3.7	-5.0	-3.2	-2.1	-14.0
Others	Revenue	0.6	0.8	0.9	0.9	3.2
	Operating profit	-0.0	0.1	1.7	2.6	4.4
Corporate expenses, etc.	Operating profit	-7.8	-6.3	-9.2	-9.5	-32.8
	Broken out: Expense related to investment in growth	-5.1	-5.1	-5.1	-5.6	-20.9
	Broken out: Expense for administration department	-3.4	-3.4	-3.5	-4.5	-14.8
	Broken out: Elimination of intersegment transactions	0.7	2.2	-0.6	0.6	2.9
Consolidated	Revenue	158.1	173.1	197.7	188.3	717.2
Consolidated	Operating profit	3.2	10.4	20.8	5.3	39.7

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2025: Financial Highlights

	FY2024/3 Actual (A)			FY2025/3 Forecast (B)			Change (B)-(A)		
Billions of Yen	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	331.2	386.0	717.2	350.0	395.0	745.0	+18.8	+9.0	+27.8
Operating profit	13.6	26.1	39.7	11.0	24.0	35.0	-2.6	-2.1	-4.7
% vs Revenue	4.1%	6.8%	5.5%	3.1%	6.1%	4.7%	-1.0P	-0.7P	-0.8P
Profit before tax	15.2	27.4	42.6	14.0	26.0	40.0	-1.2	-1.4	-2.6
% vs Revenue	4.6%	7.1%	5.9%	4.0%	6.6%	5.4%	-0.6P	-0.5P	-0.5P
Profit attributable to owners of parent	9.8	22.7	32.5	10.0	20.0	30.0	+0.2	-2.7	-2.5
% vs Revenue	3.0%	5.9%	4.5%	2.9%	5.1%	4.0%	-0.1P	-0.8P	-0.5P
ROE	5.0%			4.3%			-0.7P		
EPS	¥94.03			¥86.59			-¥7.44		
Annual Dividends	¥50			¥55			+¥5		
Exchange Rate: US\$ EURO	¥141 ¥153	¥148 ¥160	¥145 ¥157	¥145 ¥155	¥145 ¥155	¥145 ¥155	+¥4 +¥2	-¥3 -¥5	±¥0 -¥2
LONO	+133	+100	+137	7133	+ T J J	+155	1 74	+5	T C

Forecast for the year ending March 31, 2025: Performance by Segment (Segment)


		FY2024/3 Actual (A)		FY2025/3 Forecast (B)			Change (B)-(A)			
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue	137.6	142.1	279.7	150.0	150.0	300.0	+12.4	+7.9	+20.3
	Operating profit	25.2	21.3	46.5	24.0	20.0	44.0	-1.2	-1.3	-2.5
Precision Equipment	Revenue	96.0	123.3	219.3	95.0	120.0	215.0	-1.0	-3.3	-4.3
Business	Operating profit	3.2	11.9	15.1	6.0	9.0	15.0	+2.8	-2.9	-0.1
Healthcare	Revenue	51.2	56.6	107.8	55.0	60.0	115.0	+3.8	+3.4	+7.2
Business	Operating profit	2.7	2.6	5.3	3.5	7.5	11.0	+0.8	+4.9	+5.7
Components	Revenue	36.6	49.3	85.9	36.0	49.0	85.0	-0.6	-0.3	-0.9
Business	Operating profit	5.1	10.0	15.1	5.0	12.0	17.0	-0.1	+2.0	+1.9
Digital Manufacturing	Revenue	8.2	12.8	21.0	13.0	15.0	28.0	+4.8	+2.2	+7.0
Business	Operating profit	-8.7	-5.3	-14.0	-6.0	-3.5	-9.5	+2.7	+1.8	+4.5
Others	Revenue	1.4	1.8	3.2	1.0	1.0	2.0	-0.4	-0.8	-1.2
Others	Operating profit	0.1	4.3	4.4	0.0	2.5	2.5	-0.1	-1.8	-1.9
	Operating profit	-14.1	-18.7	-32.8	-21.5	-23.5	-45.0	-7.4	-4.8	-12.2
Corporate expenses, etc.	Broken out: Expense related to investment in growth	-10.2	-10.7	-20.9	-9.0	-11.0	-20.0	+1.2	-0.3	+0.9
	Broken out: Expense for administration department	-6.8	-8.0	-14.8	-12.5	-10.5	-23.0	-5.7	-2.5	-8.2
	Broken out: Elimination of intersegment transactions	2.9	0.0	2.9	0.0	-2.0	-2.0	-2.9	-2.0	-4.9
Consolidated	Revenue	331.2	386.0	717.2	350.0	395.0	745.0	+18.8	+9.0	+27.8
Consolidated	Operating profit	13.6	26.1	39.7	11.0	24.0	35.0	-2.6	-2.1	-4.7

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Financial Position

ASSET ¥1,250B 1,147.1 1,039.5 1,050.2 Cash & cash 206.6 equivalents 1,000 211.3 Trade & other 139.9 370.2 receivables 114.2 750 285.2 **Inventories** 90.5 277.2 Other current financial 500 35.5 /current assets 238.9 15.0 14.4 250 479.7 Non-current assets 432.3 325.3 0

LIABILITIES/EQUITY




23/3

24/3


22/3

Capital Expenditures, Depreciation & Amortization, and Inventories

CAPITAL EXPENDITURES, **DEPRECIATION & AMORTIZATION**




BREAKDOWN OF INVENTORIES



Note: Capital expenditures include right-of-use assets.

Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination. Inventories of FY2023/3 results have been re-stated to reflect segmentation changes. Nikon


The year ended March 31, 2024: Revenue Breakdown




BY REGION Billions of Yen Others Japan 18% 24/3 20% 130.8 23/4 144.1 17% 20% 109.5 122.9 China 17% 21% United 129.0 123.1 25% **States** 24% 159.7 17% 169.6 106.8 21% 149.4 Europe

Forecast for the year ending March 31, 2025: R&D Expenditures

R&D EXPENDITURES




R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures includes capitalization of some development expenditures.

Due to segment revision from FY2025/3, the financial figures for FY2024/3 are displayed according to the reorganized display.


Cash Flow History



Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

Imaging Products Business: Sales Units


SALES IN UNITS BY PRODUCT CATEGORY



Forecast for the year ending March 31, 2025: Precision Equipment Business Sales Units



SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)




Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".

The unit sales of new semiconductor lithography systems are 23 units in FY2021/3, 17 units in FY2022/3, 27 units in FY2023/3, 31 units in FY2024/3, and 24 units (forecast) in FY2025/3.


Precision Equipment Business: Sales Units





Precision Equipment Business: Sales Units





Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".

Forecast for the year ending March 31, 2025: Foreign Exchange Impact

	Exchange Rate	Financial Impact from Fluctuation by 1 yen				
	FY2025/3 Forecast	Revenue	Operating Profit			
US \$	¥145	Approx. ¥1.7B	Approx. ¥0.4B			
EURO	¥155	Approx. ¥0.7B	Approx. ¥0.3B			

Disclaimer Regarding Forecast and Projections

Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

